The preliminary findings revealed that PALI-2108 was safe and well tolerated in the first three cohorts at doses 15 mg, 50 mg, and 150 mg. It also demonstrated delayed release of PDE4 inhibitor active ...

Inflammatory Bowel Disease (IBD) patients are battling against the odds long before a definitive diagnosis is made.

A new thesis from Karolinska Institutet shows the significant societal economic burdens posed by two chronic inflammatory ...

The US Food and Drug Administration (FDA) has approved ustekinumab -kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...

For 1 in 7 adults, their devastating diagnosis will only be made once their symptoms get bad enough to prompt an emergency ...

The number of UC patients in China is projected to double from 2019 to 2030 to approximately one million, highlighting the urgent need for novel treatments." said Rogers Yongqing Luo, Chief Executive ...

The SELECTION study1 showed that the JAK 1 inhibitor filgotinib is safe and efficacious in ulcerative colitis. Based on positive results of the phase 2 FITZROY study2 in Crohn's disease, it was ...

The chronic condition can cause abdominal pain, diarrhea, bloody stools and fatigue. New research suggests it affects more ...

A study reveals a sharp rise in inflammatory bowel disease (IBD) among American youth, with over 100,000 under 20 affected.

In fact, as many as 35% of people with IBD have some kind of oral manifestation of the condition, such as canker sores, the ...

Results of a Phase III study conducted by an international team of researchers reveal that mirikizumab is more effective and ...

Inflammatory bowel disease (IBD) affects an estimated 1.6 million Americans. In fact, there are more than 70,000 new cases of ...